The Real Impact of Section 174: New R&D Tax Credit Changes Explained
The R&D tax credit changes you’ve been waiting for are here at last. The One Big Beautiful Bill Act (OBBBA) brings most important relief to businesses that struggle with research and development expenditure rules. Businesses can now immediately deduct their domestic research and experimental expenditures instead of capitalizing and amortizing them, starting with tax years after December 31, 2024.
This marks a fundamental change from the Tax Cuts and Jobs Act (TCJA) rules. TCJA required businesses to spread their domestic R&D deductions across five years and foreign costs over fifteen years. Small businesses that have average annual gross receipts of $31 million or less can apply these section 174 tax changes retroactively to years starting after December 31, 2021. The new R&D expensing rules interact with other tax provisions in complex ways. Note that modifications to Section 280C require domestic R&E expenditures to be reduced by the research credit amount.
This piece will explain how these section 174 R&D tax credit changes affect your business and help you learn about strategic options that can maximize your tax benefits.
The evolution of Section 174 and why it matters
Image Source: MGO CPA
Section 174 has seen dramatic changes since it first appeared in 1954. The original version let businesses deduct research and development costs right away in the year they occurred. This tax provision stayed mostly unchanged until the Tax Cuts and Jobs Act (TCJA) completely changed how businesses handled their R&D expenditures.
From immediate expensing to amortization under TCJA
The TCJA of 2017 wrapped up more than 20 years of business tax reform efforts. One of its most important yet rarely discussed provisions took away the longtime option to deduct R&D expenses immediately. Starting in tax years after December 31, 2021, businesses had to capitalize these costs and spread deductions across multiple years. This brought a radical alteration to how the tax code treated innovation investments.
The burden of 5-year and 15-year amortization rules
The TCJA rules required companies to spread domestic research costs over five years. Foreign research spending faced an even longer 15-year period. Both schedules started at the midpoint of the tax year when companies spent the money. This created major cash flow problems for companies focused on innovation. They had to wait years to fully recover their research investments through tax deductions. The forced spreading of costs didn’t match how innovation actually works – research needs upfront payment, not delayed recovery.
IRS guidance and taxpayer confusion before 2025
These changes affected many businesses deeply, yet clear regulatory guidance was hard to find. The IRS released several interim guidance documents, especially Notice 2023-63 in September 2023 and Notice 2024-12 in December 2023. Companies still struggled to figure out which costs belonged in or out, which led to compliance problems. The Treasury Department’s 2022-2023 Priority Guidance Plan noted they needed to explain “amortization of research and experimental expenditures under 174 and related issues.” Yet complete rules remained out of reach. Many taxpayers felt unsure about proper implementation while they waited for the promised Section 174 changes.
What Section 174A changes under the OB3 Act
The One Big Beautiful Bill Act (OBBBA) brings a radical alteration in R&D tax treatment through newly added Internal Revenue Code Section 174A. This new section completely changes how businesses handle research expenditures but keeps some TCJA provisions intact.
Immediate expensing for domestic R&D starting 2025
The most important r&d tax credit change restores immediate expensing for domestic research expenditures in tax years beginning after December 31, 2024. Section 174A brings back the option for full expensing that existed before TCJA. Businesses can now deduct domestic research costs in the year they occur. Companies can adopt this immediate expensing by reporting a change in accounting method with their 2025 federal income tax return.
Businesses have three options for domestic R&D treatment:
- Fully expense costs in the year incurred
- Continue capitalizing and amortizing under TCJA’s 5-year rule
- Capitalize and amortize over a period of at least 60 months
Foreign R&D still requires 15-year amortization
The favorable domestic treatment does not extend to foreign research costs, which remain under strict TCJA rules. These expenditures must be capitalized and amortized over a 15-year period. This clear difference between domestic and foreign R&D tax treatment could influence where companies decide to conduct their research activities.
Software development now qualifies for expensing
Software development expenses now explicitly qualify as research expenditures under Section 174A(d)(3). This continues TCJA’s classification of software development as R&D. Domestic costs become eligible for immediate expensing starting in 2025. The provision states that “any amount paid or incurred in connection with the development of any software shall be treated as a research or experimental expenditure”.
Section 174’s new r&d tax credit rules create valuable planning opportunities for businesses, particularly those invested heavily in domestic research and software development. Understanding these r&d expensing changes is vital to optimize tax strategies in 2025 and beyond.
How small businesses can benefit from retroactive relief
Small businesses can get a great tax break through the OBBBA’s retroactive relief provisions for R&D expenditures. They have an advantage over larger corporations because they can reclaim previously amortized research costs and might receive substantial tax refunds.
Eligibility based on $31M gross receipts threshold
Your company must have average annual gross receipts of $31 million or less for the three taxable years before 2025 to qualify as a “small business” under this provision. Your business also cannot be a tax shelter that allocates more than 35% of losses to limited partners or entrepreneurs. You should check these thresholds first since they determine your access to retroactive relief.
Amending 2022–2024 returns for refunds
Qualified small businesses can file amended returns for tax years 2022, 2023, and 2024. This lets them expense domestic R&D costs immediately instead of using the previously capitalized and amortized amounts. The deadline to make this election is July 6, 2026 – exactly one year after the bill became law. You’ll need to attach a statement with each amended return that confirms your small business status and shows your election choice.
One-year vs. two-year deduction options for unamortized costs
All businesses, whatever their size, can pick between two approaches for handling unamortized R&D costs:
- Deduct the entire remaining balance in 2025
- Split the deductions evenly between 2025 and 2026
This flexibility helps you plan your taxes based on your expected income.
Planning for the new R&D tax credit landscape
Image Source: MGO CPA
Your business needs proper planning to prepare for upcoming R&D tax credit changes. Let me show you how to get the best tax position while staying compliant.
Section 280C interaction and election strategies
The Section 280C(c) election will affect your research credit strategy. You must add back R&D credits to taxable income without this election. With it, you can claim a reduced credit (about 79% of the gross amount at the 21% corporate rate) and keep full deductions. Remember, you need to make this election on your original timely filed return. You cannot amend it later. Pass-through entities with partners in Alternative Minimum Tax situations can use a “protective” 280C election. This helps preserve future credit options without adding back expenses.
Documentation and recordkeeping best practices
The IRS needs “sufficiently usable form and detail” to prove R&D expenses. Your documentation should:
- Be created at the time of the work, not after
- Show clear links to specific projects and activities
- Connect qualified costs to business components (nexus requirement)
- Cover both technical activities and financial data
Digital records tied to specific projects work better than interviews or summaries you create later.
Scenario modeling for tax optimization
You should create several financial models with different election options and timing strategies. Look at how immediate expensing versus amortization changes your cash flow, NOLs, and overall tax liability. Smaller businesses should calculate possible refund values from retroactive relief options. The Section 280C election changes both federal and state taxes, so assess all approaches carefully.
State-level conformity and compliance gaps
States differ widely in how they follow federal R&D provisions. Some states have their own rules, so you’ll need separate tracking throughout the amortization period. This creates extra work but also gives you planning options, especially if you operate in multiple states. Some states let you make state-only elections for R&D treatment, which adds flexibility. Keep an eye on state laws – they often change after federal rules do.
Conclusion
OBBBA substantially changes how businesses handle their R&D expenditures after years of tough tax treatment under TCJA. The return to immediate expensing for domestic research costs in 2025 brings back a crucial incentive for companies driven by innovation. Small businesses with gross receipts under $31 million can now find substantial refund chances through special retroactive provisions.
Notwithstanding that, businesses need to think over several key points to maximize their tax benefits. Research conducted abroad still requires 15-year amortization, which of course creates a clear incentive to keep research within the country. On top of that, businesses must carefully assess their Section 280C election strategies, documentation practices, and state-level compliance requirements.
Working with qualified tax professionals helps model different scenarios based on your business’s unique situation. These section 174 changes offer both relief and chances – but only when businesses prepare properly. New rules give flexibility that arranges with your innovation goals and financial targets.
The tax world for research and development has altered the map without doubt. Your business can turn these technical tax changes into real financial benefits through proper planning and implementation of these new provisions while you invest in innovation that stimulates growth.
Key Takeaways
The OBBBA brings major relief to R&D-heavy businesses by restoring immediate expensing for domestic research costs starting in 2025, reversing years of challenging TCJA amortization requirements.
• Domestic R&D expensing returns in 2025: Businesses can immediately deduct domestic research costs instead of spreading them over 5 years, significantly improving cash flow.
• Small businesses get retroactive relief: Companies with under $31M average gross receipts can amend 2022-2024 returns to claim immediate R&D expensing and receive refunds.
• Foreign R&D still faces 15-year amortization: Only domestic research qualifies for immediate expensing, creating clear incentives for conducting R&D in the United States.
• Software development now explicitly qualifies: Development expenses are treated as research expenditures, making them eligible for immediate expensing under the new rules.
• Strategic planning is essential: Section 280C elections, documentation requirements, and state conformity issues require careful evaluation to maximize tax benefits.
The key is acting quickly—small businesses have until July 6, 2026, to file amended returns for retroactive relief, while all businesses should prepare documentation and election strategies for 2025 implementation.
FAQs
Q1. What are the main changes to R&D tax credits under the new legislation? The One Big Beautiful Bill Act (OBBBA) restores immediate expensing for domestic R&D costs starting in 2025, replacing the previous 5-year amortization requirement. Small businesses with average annual gross receipts of $31 million or less can apply these changes retroactively to 2022-2024. However, foreign R&D expenses still require 15-year amortization.
Q2. How can small businesses benefit from the retroactive relief provisions? Eligible small businesses can file amended returns for tax years 2022-2024 to immediately expense domestic R&D costs previously capitalized and amortized. This could result in substantial tax refunds. The election must be made by July 6, 2026, and requires attaching a statement confirming small business status.
Q3. What options do businesses have for handling unamortized R&D costs? All businesses, regardless of size, can choose between two approaches for unamortized R&D costs: deduct the entire remaining balance in 2025, or split the deductions evenly between 2025 and 2026. This flexibility allows for strategic tax planning based on projected income.
Q4. How does the Section 280C election impact R&D tax credit strategies? The Section 280C(c) election allows businesses to claim a reduced credit (about 79% of the gross amount at the 21% corporate rate) while maintaining full deductions. This election must be made on the original timely filed return and can significantly impact overall tax liability, especially for pass-through entities.
Q5. What documentation practices are recommended for R&D tax credits? The IRS requires “sufficiently usable form and detail” to substantiate R&D expenses. Best practices include maintaining contemporaneous records, connecting costs directly to specific projects, linking qualified expenses to business components, and including both technical activities and financial data. Digital, project-specific records created during development are particularly valuable for substantiation.
